// App-Quantinova.ai

: Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study

Researchers

Presenter

  • Niels Abildgaard

Principal Investigators

  • Marie-Christiane Vekemans

  • Barbara Gamberi

  • Francesco Di Raimondo

  • Angel Ramirez Payer

  • Charalampia Kyriakou

  • Alain Kentos

  • Elisabeth Kueenburg

  • Antonia Di Micco

  • Barbara Rosettani

  • Pamela Bacon

  • Margaret Atiba-Davies

  • Torben Plesner

Medical Centers

  • Department of Hematology and Academy of Geriatric Cancer Research, Odense University Hospital, University of Southern, Odense, Denmark

  • Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium

  • Oncologia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy

  • Division of Hematology, A.O.U. Policlinico Vittorio Emanuele, University of Catani, Catania, Italy

  • Hospital Universitario Central de Asturias, Calle Carretera de Rubín, Oviedo, Spain

  • University College London and Northwick Park Hospitals,London,United Kingdom

  • Hopital de Jolimont, Haine St Paul, Belgium

  • Celgene International Sarl, Boudry, Switzerland

  • Department of Hematology, University of Southern Denmark, Center Little Belt, Vejle Hospital, Vejle, Denmark

Locations

  • Denmark

  • Belgium

  • Italy

  • Spain

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Pomalidomide

  • CC-4047

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02164955

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved